Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: paclitaxel

« Back to Dashboard

Summary for Generic Name: paclitaxel

Drug Master File Entries: see list63
Suppliers: see list2

Pharmacology for Ingredient: paclitaxel

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: paclitaxel

Hepatic Arterial Infusion (HAI) of Abraxane
Status: Active, not recruiting Condition: Liver Cancer; Advanced Cancers; Solid Tumors

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Status: Completed Condition: Breast Cancer

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Status: Recruiting Condition: Resectable Pancreatic Adenocarcinoma

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Status: Recruiting Condition: Bladder Cancer

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Status: Recruiting Condition: Advanced Cancer

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Status: Terminated Condition: Breast Neoplasms; Neoplasm Metastasis

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Recruiting Condition: Melanoma

Pharmacokinetic and Safety Study of NabĀ®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia
Status: Not yet recruiting Condition: Pancreatic Neoplasms; Cholestasis

HAI Abraxane With Gemcitabine and Bevacizumab
Status: Completed Condition: Advanced Cancers

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes<disabled><disabled>
Pliva Lachema
INJECTABLE;INJECTION077413Mar 12, 2008DISCNNo<disabled><disabled>
Abraxis Bioscience
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,853,260<disabled>Y<disabled>
Accord Hlthcare
INJECTABLE;INJECTION075436Nov 12, 2004DISCNNo<disabled><disabled>
Onco Therapies Ltd
INJECTABLE;INJECTION091540Sep 29, 2011RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology